Literature DB >> 27822591

[Memantine as add-on medication to acetylcholinesterase inhibitor therapy for Alzheimer dementia].

R Haussmann1, M Donix2.   

Abstract

Currently available data indicate superior therapeutic effects of combination treatment for Alzheimer dementia with memantine and acetylcholine esterase inhibitors in certain clinical contexts. Out of five randomized, placebo-controlled, double-blind trials two showed superior therapeutic effects in comparison to monotherapy with acetylcholinesterase inhibitors regarding various domains. Recently published meta-analyses and cost-benefit analyses also showed positive results. Recently published German guidelines for dementia treatment also take these new data into account and recommend combination treatment in patients with severe dementia on stable donepezil medication. This article gives an overview of current evidence for combination therapy.

Entities:  

Keywords:  Acetylcholinesterase inhibitors; Add-on treatment; Alzheimer’s disease; Memantine; Pharmacotherapy

Mesh:

Substances:

Year:  2017        PMID: 27822591     DOI: 10.1007/s00115-016-0237-3

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  26 in total

1.  Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative.

Authors:  Lon S Schneider; Philip S Insel; Michael W Weiner
Journal:  Arch Neurol       Date:  2011-01

Review 2.  Namzaric--a combination of 2 old drugs for Alzheimer's disease.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  2015-07-20       Impact factor: 1.909

3.  Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.

Authors:  Hyun Jeong Han; Byeong C Kim; Jun-Young Lee; Seung-Ho Ryu; Hae Ri Na; Soo Jin Yoon; Hyun Young Park; Joon Hyun Shin; Soo-Jin Cho; Hyon-Ah Yi; Mun Seong Choi; Jae-Hyeok Heo; Kyung Won Park; Kwang K Kim; Seong Hye Choi
Journal:  Dement Geriatr Cogn Disord       Date:  2012-10-05       Impact factor: 2.959

4.  Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease.

Authors:  Hyun Jeong Han; Jay C Kwon; Jung Eun Kim; Shin Gyeom Kim; Jong-Moo Park; Kyung Won Park; Key Chung Park; Kee Hyung Park; So Young Moon; Sang Won Seo; Seong Hye Choi; Soo-Jin Cho
Journal:  Eur Neurol       Date:  2014-11-01       Impact factor: 1.710

5.  Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.

Authors:  O L Lopez; J T Becker; A S Wahed; J Saxton; R A Sweet; D A Wolk; W Klunk; S T Dekosky
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-02-09       Impact factor: 10.154

6.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

Authors:  Pierre N Tariot; Martin R Farlow; George T Grossberg; Stephen M Graham; Scott McDonald; Ivan Gergel
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

7.  A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease.

Authors:  Christopher H van Dyck; Pierre N Tariot; Barnett Meyers; E Malca Resnick
Journal:  Alzheimer Dis Assoc Disord       Date:  2007 Apr-Jun       Impact factor: 2.703

8.  Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementias.

Authors:  Taim Muayqil; Richard Camicioli
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2012-11-23

9.  Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis.

Authors:  Alireza Atri; Suzanne B Hendrix; Vojislav Pejović; Robert K Hofbauer; John Edwards; José Luis Molinuevo; Stephen M Graham
Journal:  Alzheimers Res Ther       Date:  2015-05-18       Impact factor: 6.982

Review 10.  Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease.

Authors:  Chris G Parsons; Wojciech Danysz; Andrzej Dekundy; Irena Pulte
Journal:  Neurotox Res       Date:  2013-05-09       Impact factor: 3.911

View more
  1 in total

1.  Identification of the optimal cognitive drugs among Alzheimer's disease: a Bayesian meta-analytic review.

Authors:  Jinghong Liang; Jiayu Li; Ruixia Jia; Yingquan Wang; Rongkun Wu; Hongbo Zhang; Lei Hang; Yong Xu
Journal:  Clin Interv Aging       Date:  2018-10-18       Impact factor: 4.458

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.